Amyris Biotechnologies Inc. (AMRS) Reports Larger Q1 Loss
Tweet
Share
E-mailGet Alerts AMRS Hot Sheet
Join SI Premium – FREE
Amyris Biotechnologies Inc. (NASDAQ: AMRS) reported Q1 EPS of ($0.76), $0.26 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $37.2 million versus the consensus estimate of $31.48 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
- Stardust Power (SDST) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
